Scholar Rock Holding Corporation (SRRK) exhibits 44.0% gross margins and -35.0% return on invested capital within Health Care (Biotechnology: Biological Products (No Diagnostic Substances)), balanced against a 24.0x enterprise multiple and 7.0% implied options volatility.
Sustained 44.0% gross profitability converts into 16.5% operating margin and -35.0% ROIC, outpacing sector cost of capital.
ROIC: -35.0% // GM: 44.0%YoY revenue trajectory of +7.7% paired with -5.59% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +7.7% // FCF YLD: -5.59%Altman Z-Score of 13.67 and Piotroski F-Score of 5/9 indicate low near-term refinancing stress.
ALTMAN Z: 13.67 // F-SCORE: 5/9Trading at 24.0x trailing P/E (32.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: —Options market prices a ±7.0% implied move with a 0.76 put/call ratio around $43.00 max pain.
IMPL MOVE: ±7.0% // P/C: 0.76Elevated industry capital intensity and customer concentration in Biotechnology: Biological Products (No Diagnostic Substances) require continuous execution to defend 12.4% net margins.
NET MARGIN: 12.4% // D/E: 0.41x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for SRRK & activate live FRED threshold breach alerts.